- Home
- TPIC vs AVTX Comparison
TPIC vs AVTX Comparison
Compare TPIC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- AVTX
- Stock Information
- Founded
- TPIC 1968
- AVTX 2011
- Country
- TPIC United States
- AVTX United States
- Employees
- TPIC N/A
- AVTX N/A
- Industry
- TPIC Industrial Machinery/Components
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- TPIC Industrials
- AVTX Health Care
- Exchange
- TPIC Nasdaq
- AVTX Nasdaq
- Market Cap
- TPIC 58.4M
- AVTX 57.4M
- IPO Year
- TPIC 2016
- AVTX 2015
- Fundamental
- Price
- TPIC $0.79
- AVTX $7.75
- Analyst Decision
- TPIC Hold
- AVTX Strong Buy
- Analyst Count
- TPIC 7
- AVTX 7
- Target Price
- TPIC $1.68
- AVTX $31.00
- AVG Volume (30 Days)
- TPIC 475.4K
- AVTX 127.8K
- Earning Date
- TPIC 08-11-2025
- AVTX 08-11-2025
- Dividend Yield
- TPIC N/A
- AVTX N/A
- EPS Growth
- TPIC N/A
- AVTX N/A
- EPS
- TPIC N/A
- AVTX N/A
- Revenue
- TPIC $1,373,242,000.00
- AVTX $441,000.00
- Revenue This Year
- TPIC $10.73
- AVTX N/A
- Revenue Next Year
- TPIC $5.56
- AVTX N/A
- P/E Ratio
- TPIC N/A
- AVTX N/A
- Revenue Growth
- TPIC 3.05
- AVTX N/A
- 52 Week Low
- TPIC $0.64
- AVTX $3.39
- 52 Week High
- TPIC $5.15
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- TPIC 39.96
- AVTX 73.19
- Support Level
- TPIC $0.78
- AVTX $6.21
- Resistance Level
- TPIC $0.91
- AVTX $7.11
- Average True Range (ATR)
- TPIC 0.07
- AVTX 0.47
- MACD
- TPIC 0.00
- AVTX 0.08
- Stochastic Oscillator
- TPIC 27.67
- AVTX 89.21
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).